Suneja Gita, Coghill Anna
aDepartment of Radiation Oncology, Duke University, Duke Global Health Institute, Durham, North Carolina, USA bNational Cancer Institute, Bethesda, Maryland, USA.
Curr Opin HIV AIDS. 2017 Jan;12(1):63-68. doi: 10.1097/COH.0000000000000320.
Cancer is a growing problem in the HIV population, in large part because of aging of HIV-infected people treated with antiretroviral therapy. Overall and cancer-specific survival is worse in HIV-infected cancer patients compared with uninfected patients. One potential reason for the observed survival deficit is differences in cancer treatment.
Recent population-based data suggest that HIV-infected cancer patients are less likely to receive cancer treatment compared with uninfected patients. This review describes these treatment disparities and their impact on patient outcomes, explores reasons for the disparity and highlights areas for future research.
Cancer is the leading cause of non-AIDS death in HIV-infected individuals. Understanding the underlying cancer treatment disparity between HIV-infected patients and their uninfected counterparts, and developing solutions to address the problem, is of great importance to improve cancer outcomes in this growing patient population.
癌症在HIV人群中是一个日益严重的问题,很大程度上是因为接受抗逆转录病毒治疗的HIV感染者老龄化。与未感染患者相比,HIV感染的癌症患者的总体生存率和癌症特异性生存率更差。观察到的生存差距的一个潜在原因是癌症治疗的差异。
最近基于人群的数据表明,与未感染患者相比,HIV感染的癌症患者接受癌症治疗的可能性更小。本综述描述了这些治疗差异及其对患者预后的影响,探讨了差异的原因,并突出了未来研究的领域。
癌症是HIV感染者中非艾滋病死亡的主要原因。了解HIV感染患者与其未感染 counterparts之间潜在的癌症治疗差异,并制定解决该问题的方案,对于改善这一不断增长的患者群体的癌症预后至关重要。